摘要
Globally,hepatocellular carcinoma(HCC)is associated with a poor prognosis due to frequent diagnosis in late stages.As a result,mortality is roughly equivalent to the annual incidence.Regardless of etiology,the development of liver cirrhosis is the most relevant cause of hepatocarcinogenesis^([1]).Chronic hepatitis B virus(HBV)infection and nonalcoholic steatohepatitis(NASH)are associated with a significantly increased risk of developing HCC even in the absence of cirrhosis^([2]).Recent data demonstrate that NASH has to be considered as the main cause of the increasing incidence of HCC predicted for the next decades^([3]).Thus,against the background of high mortality,the need for optimized HCC screening strategies arises on the one hand,while,on the other hand,previous treatment concepts have to be adapted to the sometimes therapy-limiting comorbidities of these patients.
